Tighe Reardon Sells 822,721 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANXGet Free Report) CFO Tighe Reardon sold 822,721 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $54.75, for a total transaction of $45,043,974.75. Following the sale, the chief financial officer now directly owns 633,673 shares of the company’s stock, valued at approximately $34,693,596.75. The sale was disclosed in a filing with the SEC, which is available at this link.

Janux Therapeutics Price Performance

NASDAQ:JANX opened at $42.59 on Friday. The company’s 50-day moving average is $48.32 and its two-hundred day moving average is $28.25. Janux Therapeutics, Inc. has a 1-year low of $5.65 and a 1-year high of $65.60. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of -34.91 and a beta of 3.71.

Janux Therapeutics (NASDAQ:JANXGet Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.05. Janux Therapeutics had a negative net margin of 762.92% and a negative return on equity of 13.49%. The firm had revenue of $1.25 million for the quarter, compared to analyst estimates of $0.98 million. As a group, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.34 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Wedbush upped their price objective on shares of Janux Therapeutics from $53.00 to $74.00 and gave the company an “outperform” rating in a research note on Wednesday, May 8th. HC Wainwright upped their price objective on shares of Janux Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Monday, May 13th. Jonestrading began coverage on shares of Janux Therapeutics in a research note on Tuesday, April 16th. They set a “buy” rating and a $70.00 price objective for the company. BTIG Research began coverage on shares of Janux Therapeutics in a report on Thursday, March 21st. They issued a “buy” rating and a $62.00 target price on the stock. Finally, William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $66.29.

Check Out Our Latest Report on Janux Therapeutics

Hedge Funds Weigh In On Janux Therapeutics

Several large investors have recently made changes to their positions in JANX. Barclays PLC lifted its holdings in shares of Janux Therapeutics by 227.1% in the 3rd quarter. Barclays PLC now owns 17,922 shares of the company’s stock worth $181,000 after acquiring an additional 12,443 shares during the last quarter. FMR LLC lifted its holdings in shares of Janux Therapeutics by 25.5% in the 3rd quarter. FMR LLC now owns 6,351,322 shares of the company’s stock worth $64,021,000 after acquiring an additional 1,288,526 shares during the last quarter. Old Well Partners LLC acquired a new position in shares of Janux Therapeutics in the 3rd quarter worth approximately $104,000. Corton Capital Inc. acquired a new position in shares of Janux Therapeutics in the 3rd quarter worth approximately $111,000. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in Janux Therapeutics by 27.8% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,150,000 shares of the company’s stock worth $11,592,000 after buying an additional 250,000 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

About Janux Therapeutics

(Get Free Report)

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Recommended Stories

Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.